Menu Search
Equities

Diamyd Medical AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert
DMN:MUN

Diamyd Medical AB

Actions
  • Price (EUR)1.62
  • Today's Change-0.034 / -2.05%
  • Shares traded5.30k
  • 1 Year change+7.20%
  • Beta1.1337
Data delayed at least 15 minutes, as of Feb 06 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.

  • Revenue in SEK (TTM)348.00k
  • Net income in SEK-182.46m
  • Incorporated1984
  • Employees41.00
  • Location
    Diamyd Medical ABKungsgatan 29STOCKHOLM 111 56SwedenSWE
  • Phone+46 86610026
  • Fax+46 86616368
  • Websitehttps://www.diamyd.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.